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Abstract
PK 11195 and DAA1106 bind with high-affinity to the translocator protein (TSPO, formerly known as the peripheral
benzodiazepine receptor). TSPO expression in glial cells increases in response to cytokines and pathological stimuli.
Accordingly, [
11C]-PK 11195 and [
11C]-DAA1106 are recognized molecular imaging (MI) agents capable of monitoring
changes in TSPO expression occurring in vivo and in response to various neuropathologies. Here we tested the
pharmacological characteristics and TSPO-monitoring potential of two novel MI agents: NIR-conPK and NIR-6T. NIR-conPK is
an analogue of PK 11195 conjugated to the near-infrared (NIR) emitting fluorophore: IRDye 800CW. NIR-6T is a DAA1106
analogue also conjugated to IRDye 800CW. We found that NIR-6T competed for [
3H]-PK 11195 binding in astrocytoma cell
homogenates with nanomolar affinity, but did not exhibit specific binding in intact astrocytoma cells in culture, indicating
that NIR-6T is unlikely to constitute a useful MI agent for monitoring TSPO expression in intact cells. Conversely, we found
that NIR-conPK did not compete for [
3H]-PK 11195 binding in astrocytoma cell homogenate, but exhibited specific binding
in intact astrocytoma cells in culture with nanomolar affinity, suggesting that NIR-conPK binds to a protein distinct, but
related to, TSPO. Accordingly, treating intact astrocytoma cells and microglia in culture with cytokines led to significant
changes in the amount of NIR-conPK specific binding without corresponding change in TSPO expression. Remarkably, the
cytokine-induced changes in the protein targeted by NIR-conPK in intact microglia were selective, since IFN-c (but not TNFa
and TGFb) increased the amount of NIR-conPK specific binding in these cells. Together these results suggest that NIR-conPK
binds to a protein that is related to TSPO, and expressed by astrocytomas and microglia. Our results also suggest that the
expression of this protein is increased by specific cytokines, and thus allows for the monitoring of a particular subtype of
microglia activation.
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Introduction
Molecular imaging (MI) agents allow for the non-invasive
monitoring of molecular events in intact cells and tissues. They
include high affinity receptor ligands that are labeled with
radioactive isotopes or conjugated to biocompatible imaging
moieties. Thus, the signal emitted by MI agents – be it
radioactivity or light–fluctuates in parallel with any change in
the expression of the targeted receptor.
MI agents targeting the mitochondrial translocator protein
(TSPO, formerly known as the peripheral benzodiazepine
receptor [1]) have been developed and the signal that they emit
shown to fluctuate in parallel with changes in TSPO expression in
glial cells, as well as the progression of some neuropathologies. For
example, [
11C]-PK 11195 reliably monitors increases in TSPO
expression in brain tumors (including malignant astrocytomas), as
well as in the activated microglia found in patients with multiple
sclerosis, stroke, epilepsy, Alzheimer’s disease, Huntington’s
disease and AIDS [2,3,4,5,6,7,8,9,10]. Another MI agent, [
11C]-
DAA1106, which exhibits even higher affinity for TSPO than PK
11195, is also used to monitor TSPO expression in activated
microglia [11,12,13,14,15].
Evidence suggests that moieties emitting light in the near
infrared range (NIR, 700–1000 nm) hold promise for the
development of MI agents, and in fact several such MI agents
have been tested for their ability to monitor molecular events both
in vitro and in vivo [16,17,18]. NIR fluorescence can be detected
with high sensitivity and is relatively transparent to biological
matrices (lipids, water and hemoglobin neither absorb nor auto-
fluoresce significantly in the NIR range [19]). However, it is
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8271important to note that moieties emitting NIR fluorescence are
hydrophobic and large in mass, and therefore their conjugation to
receptor ligands may affect the ligand’s affinity and selectivity
towards its target. Thus the pharmacological characteristics of any
newly developed MI agent emitting NIR fluorescence – their
purity and especially their affinity and selectivity at the targeted
receptor – should be systematically verified.
The present study focuses on two new MI agents originally
designed to target TSPO: chemical analogues of PK 11195 and
DAA1106 conjugated to a NIR-emitting fluorophore (these MI
agents were named NIR-conPK and NIR-6T, respectively)
[20,21,22]. For both these MI agents, we tested the following
three criteria: Do they bind to TSPO in cell homogenates and
intact cells? Does the signal that these MI agents emit fluctuate
reliably as a function of changes in TSPO expression? How do
fluctuations in the signal emitted by these MI agents correlate with
a particular subtype of immune cell activation?
Materials and Methods
Chemicals
PK 11195 was from Sigma (St. Louis, MO), DAA1106 was
synthesized as described [23], IFNc, TNFa and TGFb2 were from
R&D systems (Minneapolis, MN), CellGroH was from Mediatech
(Washington DC), DRAQ-5 from Axxora (San Diego, CA), WST1
from Roche Applied Science (Indianapolis, IN) and the IRDye
800CW dye was from LI-Cor biosciences (Lincoln, Nebraska).
Synthesis and Characterization of MI Agent
Analogues of PK 11195 (conPK 11195: herein referred to as
conPK) and DAA1106 (6-TSPOmbb732: herein referred to as 6T)
were synthesized for conjugation to a fluorophore as described,
and their chemical structure (Fig. S1), synthesis yield and
characterization by spectroscopy have been previously reported
[21,24]. IRDye 800 CW is a fluorophore with absorption
max=778 nm and emission max=806 nm. The dye bears a
reactive N-hydroxy-succinimide reactive group allowing for facile
conjugation to ligands of interest (Fig. S1). Briefly, a mixture of
IRDye 800CW and conPK or 6-T was stirred in anhydrous
dimethylsulfoxide in an Argon flushed vessel, in the dark at room
temperature for 18 hrs. Reaction progress was followed by HPLC
analysis using a C18 column (Varian, Inc. Palo Alto, CA) and
eluting the compounds with acetonitrile: water. Compounds were
further purified on an open alumina column eluting with
acetonitrile: water, followed by an ion exchange column eluting
with water. Pure fractions were then concentrated using rotary
evaporation and dried with lyopholization. Nuclear Magnetic
Resonance characterized the imaging agent, and Electrospray
Ionization Mass Spectrometry calculated: 1364.01 (M
2+ 681.95).
Spectroscopic characterization in both water and DMSO
consisted of both UV/vis Shimadzu 1701 spectrophotometer
(Shimadzu Scientific Instruments, Columbia, MD) and fluorimetry
(Photon Technology International, Birmingham, NJ).
Cell Culture
DBT and BV-2 cells were grown in DMEM supplemented with
FBS (10%). Mouse microglia in primary culture were prepared as
described [25,26] according to the guidelines of the Institutional
Animal Care and Use committee of the University of Washington.
qPCR
Total RNA from cells and tissues were extracted using Qiagen
RNeasy. qPCR was performed using Taqman probes. Acidic
ribosomal binding protein (ARBP) was used as a housekeeping gene
[27](controlforequalRNAinput)inallruns.Itslevelsdidnotchange
significantly between control and treatment conditions (data not
shown). Thus, samples were normalized to the ARBP endogenous
control using a Dct-based algorithm (ctTSPO-ctARBP) yielding
arbitrary units that represent relative expression levels between
samples. Primers were: ARBP: forward=59-GGTGTTTGACAAC-
GACAGCATT-39; reverse=59-CAGGGCCTGCTCTGTGATG-
T-39. Mouse TSPO: forward=59-CAT GGG GTA TGG CTC
CTA CA-39; reverse=59-AGA CCC AAG GGA ACC ATA GC-39
Filtration Radioligand Binding Assay
Enriched membranes were prepared according to [28]. Briefly,
mitochondrial-enriched membranes from DBT cells were pre-
pared by lysing cells with ice-cold homogenization buffer (50 mM
Tris, 1 mM EDTA and 3 mM MgCl2), followed by dounce
homogenization (five gentle strokes). Homogenates were centri-
fuged (40,0006g, 15 min, 4uC) and cell pellet resuspended in
0.5 ml homogenization buffer, re-homogenized by dounce (five
gentle strokes while on ice) and centrifuged again (40,0006g,
15 min, 4uC). Cell pellets were stored at 280uC until further use.
Radioligand binding assays were performed in silanized glass test
tubes (Kimble Glass Inc.). The following components were added:
50 ml of non-radiolabeled DAA1106 or PK 11195, 50 ml of [N-
methyl-
3H]-PK 11195 (PerkinElmer, Boston MA; 250 mCi,
84.8 Ci/mmol) and 100 ml of protein (50 mg, which started the
incubation) for a total volume of 200 ml in binding buffer (50 mM
Tris, 1 mM EDTA, 3 mM MgCl2 and 0.1% BSA), all of which
was placed in a water bath (30uC) with mild agitation for 1 hr.
Incubation was stopped by rapid filtration and rinsing with ice-
cold binding buffer, using the Brandel harvester (Gaithersburg,
MD) and Whatman GFB filter paper (Brandel, Gaithersburg MD).
Filters were then transferred to 7 ml glass scintillation vials (VWR,
West Chester PA). Five ml of Ecoscint XR scintillation fluid
(National Diagnostics, Atlanta, GA) was added, followed by 10 sec
vortexing and ,18 hrs incubation at room temperature prior to
determining the radioactivity with a scintillation counter (Perki-
nElmer, Boston MA).
Intact Cell Binding Assay
We developed the intact cell binding assay described here for
the first time: DBT or primary microglia cells at 5610
4 per 200 ml
of DMEM+10% FBS were seeded in 96 well plates with optical
bottom polymer (NUNCH). Twenty-four hours later, cells typically
reached a density of ,80% confluence. Cells were then rinsed
once in MEM supplemented with 10% CellgroH, pre-incubated
with PK 11195, DAA1106 or vehicle, and then incubated with
NIR-conPK or NIR-6T. Rinsing once with MEM/Cellgro
stopped the incubation. Fluorescence at 800 nm was quantified
with a Li-Cor OdysseyH Infrared Imaging System (LI-COR
Biosciences, Lincoln, NE). Cells were then fixed in 4% PFA
(10 min), rinsed twice with PBS/0.2% Triton (5 min) and four
times with PBS. Cells were then incubated in Odyssey Blocking
Buffer (90 min) and rinsed three times in PBS. DRAQ-5 (a dye
that binds rapidly to DNA, is compatible with live cells and emits
at 700 nM) was added for 5 min, allowing for precise determina-
tion of cell density in each well. These values were used to correct
the signal read at 800 nM in each well. The values for non-specific
binding were subtracted from total binding values (with data
expressed in terms of relative fluorescence units, RFU).
Cell Activation
DBT or primary microglia cells were treated with TNFa/
IFNc/TGFb2 for 24 hrs, and supernatants (50 ml) collected for
quantification of cytokine/chemokine levels using the mouse
NIR-TSPO Optical Imaging
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Charlottesville, VA) and the LuminexH platform (Qiagen,
Alameda, CA). For cell proliferation assay, we used WST-1
reagent. Specifically, 10 ml of WST-1 (per 100 ml of media) was
added to each well and incubated for 2 hrs. Absorption was read
with a Hewlett-Packard SpectracountH microplate reader (Palo
Alto, CA) at 450 nm, using 590 nm as reference.
Western Blots
Microglia cells treated with cytokines for 24 hrs were rinsed in
PBS and lysed in Triton X 100 ice-cold lysis buffer (50 mM Tris
HCl pH 7.5, containing 0.5% Triton X 100, 150 mM NaCl,
2 mM PMSF, one cocktail of protease inhibitors/50 ml, Roche
Applied Science). The lysed cells were then centrifuged at 13006g
at 4Cu (30 min). The resulting supernatant was then recovered for
protein quantification and 40 mg of protein was sonicated and
heated at 95Cu prior to loading on to each lane of a NuPAGE
Novex4–12%Bis-Tris gradient gel. After electrophoretically trans-
ferring the proteins to a nitrocellulose membrane, a Panceau S
staining was conducted to visualize the proteins. The membrane
was then blocked with 5% milk in PBS for one hr and
immunoblotted for PBR (1:1000, as kind gift from Dr. Vasilli
Papadopolous) and GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase, 1:10000). The 18 Kd PBR and the 36 Kd GAPDH
subunits were visualized using PierceH Enhanced Chemilumines-
cent (ECL) Western Blotting Substrate (Thermo Scientific, Rock-
ford, IL.) and horseradish peroxidase-goat anti-rabbit and
horseradish peroxidase-goat anti-mouse secondary anti-sera used
at 1:10,000 and 1:4,000 dilutions, respectively). The membrane
was exposed over hyperfilm ECL (GE healthcare Amersham) and
the densities of the bands quantified by Image J (Image Processing
and Analysis in Java, NIH).
Calculations and Statistical Analysis
Data are expressed as n=number of determinations (three per
independent experiment). Statistical analysis, Kd and Ki values
were calculated using non-linear regression with a one binding site
hyperbola, where X is the concentration of the ligand, Y is specific
binding and Bmax and Kd are determined using this equation:
Y=B max X/Kd+X calculated by GraphPad Prism 4.
Results
To determine the pharmacological characteristics of the new
MI agents targeting TSPO that we are studying, we required a cell
line that expresses relatively high levels of TSPO. Using qPCR, we
found that DBT cells, a highly malignant mouse astrocytoma cell
line [29], express high levels of TSPO mRNA compared to two
other mouse astrocytoma cell lines, D30 and D1A cells (Table 1)
[30]. By comparison, levels of TSPO mRNA in DBT cells were
also higher than in healthy mouse brain, mouse microglia in
primary culture and BV-2 cells (a mouse microglia cell line)
(Table 1) [31]. High TSPO expression in DBT cells was confirmed
by filtration radioligand binding assays using [
3H]-PK 11195 (we
detected 14 pmol of TSPO per gram of protein, Fig. 1A, Table 2).
Increasing concentrations of PK 11195 and DAA1106 competed
for [
3H]-PK 11195 binding with Ki of 2.0 and 0.2 nM, respectively
(Fig. 1B, C), values that are well within the range of what has been
reported [32]. These results show that DBT cells express relatively
high levels of TSPO and therefore constitute a reliable cell model
to determine the pharmacological characteristics of agents
targeting TSPO with nanomolar affinity.
Using DBT cell homogenates, we then tested whether NIR-
conPK and NIR-6T compete for [
3H]-PK 11195 binding, and
found that NIR-conPK was relatively ineffective (with 10 mM
displacing only ,15% of [
3H]-PK 11195 binding) (Fig. 1B),
whereas NIR-6T competed for [
3H]-PK 11195 binding with a Ki
of 412 nM (Fig. 1C). These results show that the addition of an
NIR moiety to con-PK greatly reduces its affinity at TSPO (to the
point that it does not significantly bind to this protein anymore).
Furthermore, the addition of an NIR moiety to 6T reduces its
affinity by ,2000 fold, but this MI agent still binds significantly to
TSPO.
Radioligand binding performed on cell homogenate represents
the gold standard for the pharmacological characterization of the
binding of ligands to their targets [33].Yet evidence shows that the
local microenvironments found in intact cells, which include local
ionic concentrations and protein-protein interactions, greatly
influences the pharmacological characteristics with which ligands
bind to their targets [34,35,36]. This prompted us to test whether
NIR-conPK and NIR-6T bind to TSPO in intact DBT cells. To
do so, we developed an assay to measure specific binding in intact
cells by quantifying NIR fluorescence, and varied the parameters
required to optimize specific binding based on what had been
described for radioligand binding assay performed in intact cells
[37]. Specifically, we cultured DBT cells in 96 well plates, and
optimized growing and total binding conditions by varying cell
density, culture media, presence or absence of serum, type of
plates, coatings plates with extracellular matrices, pre-incubation
times and challenge versus competition experiments. We opted for
plating the cells at ,80% confluence at the time of experimen-
tation, in defined media void of serum and in optical black-sided
well plates, all of which resulted in the least non-specific binding to
the plate, reduced light scattering and gave the greatest percent of
specific binding. Thus, we incubated the cells under those
conditions with either NIR-conPK or NIR-6T, rinsed the cells
once (to remove unbound MI agents) and then quantified the
amount of MI agent that had remained bound to intact cells with a
LI-COR OdysseyH Infrared Imaging system [38].
The first parameter that we sought to determine was the
amount of time required for these MI agents to reach binding
equilibrium with intact cells. Total binding of NIR-conPK to DBT
cells started to plateau after 60 min, while no such equilibrium was
reached with NIR-6T, even after 4 hrs (Fig. 2As, B). Second, when
using a 60 min incubation time, we verified that increasing
concentration of both NIR-conPK and NIR-6T resulted in linear
increases in fluorescence, and indeed found a linear correlation
Table 1. qPCR determination of TSPO mRNA levels in cells
and tissue.
Cell Line/Tissue Type D CT Fold Increase
DBT 1.93 21.4
Primary Microglia 3.58 6.8
D30 4.57 3.4
Spleen 4.81 2.9
D1A 5.17 2.3
BV-2 6.14 1.2
Brain 6.35 1
Cell and tissue mRNA were extracted, and TSPO and ARBP (house-keeping
gene) mRNA levels determined by qPCR, as outlined in the material and
methods section. Relative levels are expressed by normalized values using a
Dct-based algorithm (ctTSPO-ctARBP). Fold increase compared to the lowest
level of our sampling (brain) was calculated as outlined in the method section.
doi:10.1371/journal.pone.0008271.t001
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DBT cells in a time- and concentration-dependent manner,
although NIR-6T does not reach equilibrium, even after several
hrs.
To determine how much of this total binding of NIR-conPK
and NIR-6T to intact cells is due to their specific binding to
TSPO, we pre-treated intact DBT cells with either PK 11195
(10 mM) or DAA1106 (10 mM) to saturate TSPO, and assessed
whether this pre-treatment reduces the amount of NIR-conPK
and NIR-6T bound to intact cells. Remarkably, we found that the
total binding of NIR-6T was not affected by either PK 11195 or
DAA1106 (Fig. 2D), whereas the total binding of NIR-conPK was
reduced by ,25% by PK 11195 and ,50% by DAA1106
(Fig. 2C), suggesting that NIR-conPK exhibits some amount of
specific binding. Increasing the concentration of NIR-conPK yield
a Kd of 120 nM when using an excess of PK 11195 (Fig. 2E) and a
Kd of 85 nM when using an excess of DAA1106 (Fig. 2F). There
are two possible interpretations of these results. One is that the
pharmacological characteristics of NIR-conPK and NIR-6T
binding to TSPO are opposite when using either cell homogenates
or intact cells, with only NIR-6T binding to TSPO in cell
homogenates, while only NIR-conPK binds to TSPO in intact
cells. Another interpretation is that neither NIR-6T or NIR-
conPK bind to TSPO in intact cells, and NIR-conPK binds to a
protein distinct from TSPO that exhibits a pharmacological profile
closely related to that of TSPO (since its binding is competed by
both PK 11195 and DAA1106).
To distinguish between these two possibilities, we sought to
determine if the amount of specific binding measured for NIR-
conPK correlates with TPSO expression. To perform these
experiments, we used primary microglia in culture, because a
positive correlation between immune cell activation and increases
in TSPO expression has been reported [39,40,41,42]. Thus we
treated primary microglia in culture with TNFa, IFNc or IFNc/
TNFa, all of which activate microglia toward a pro-inflammatory
phenotype, or with TGFb2, which inactivates microglia. Twenty
four hrs later, we quantified the amount of specific binding
obtained with NIR-conPK, as well as the expression levels of
TSPO (by both qPCR and western blot). We found that IFNc led
to a significant increase in the amount of specific binding exhibited
by NIR-conPK in intact microglia, whereas TNFa, TNFa+IFNc
and TGFb2 did not (Fig. 3A). Importantly, the increase in NIR-
conPK specific binding was not associated with a change in TSPO
protein and mRNA (Fig. 3C and Fig. S3A). Please note that the
Table 2. Kd and Bmax of [
3H]-PK 11195 binding using
homogenates prepared from cytokine-treated DBT cells.
Conditions Bmax Ki
Control 14.0+/21.1 4.3+/20.65
IFNc 17.0+/22.6 4.7+/20.7
TNFa 17.4+/22.9 5.3+/21.2
IFNc+TNFa 17.6+/22.4 5.2+/20.9
TGFb2 22.1+/24.7 6.5+/21.9
DBT cells incubated for 18–24 hrs with either vehicle (basal), TNFa (5 ng/ml),
IFNc (100 Ui/ml), TNFa+IFNc,o rT G F b2 (1 ng/ml). Cells were harvested,
homogenates prepared and [
3H]-PK 11195 Kd and Bmax determined as
outlined in the materials and methods section. Values are mean6SEM of 12–15
measurements (i.e. four or five independent experiments, each performed in
duplicate). We found no significant difference in Kd and Bmax between basal
and respective cytokine-treated conditions, as determined by ANOVA followed
by Dunnett’s.
doi:10.1371/journal.pone.0008271.t002
Figure 1. Ability of NIR-conPK and NIR-6T to compete for [
3H]-
PK 11195 binding to DBT cell homogenates. (A) Representative
specific binding of [
3H]-PK 11195 to DBT cell homogenates (average
Bmax and Kd are in Table 2). (B) Competition of specific [
3H]-PK 11195
binding to DBT cell homogenates by increasing concentrations of PK
11195 (dotted line) or NIR-conPK (solid line). Ki and EC50 values for PK
11195 competition were 41 and 93 nM respectively, and calculated
using three independent experiments, each performed in triplicate. Ki
value for NIR-conPK could not be reliably calculated, indicating that this
MI agent does not bind to TSPO. (C) Competition of specific [
3H]-PK
11195 binding to DBT cell homogenates by increasing concentrations
of 6T (dotted line) and NIR-6T (solid line). Ki and EC50 values for 6T were
3.6 and 114 nM respectively and for NIR-6T 400 and 412 nM and were
calculated using three independent experiments, each performed in
triplicate.
doi:10.1371/journal.pone.0008271.g001
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density (Fig. S3C). Thus, changes in NIR-conPK specific binding
do not correlate with changes in TSPO expression, and are likely
due to the change in expression of a distinct protein.
We then performed similar experiments in DBT cells and also
found no correlation, since here IFNc+TNFa and TGFb2
treatments led to a significant decrease in the amount of NIR-
conPK specific binding in intact DBT cells (Fig. 3B), without
Figure 2. NIR-conPK and NIR-6T binding in intact DBT cells. (A, B) Kinetics of the total binding when labeling intact DBT cells with 100 nM of
either NIR-conPK (A) or NIR-6T (B). (C, D) Ability of PK 11195 and 6T to compete for the binding of (C) NIR-conPK and (D) NIR-6T in intact DBT cells.
DBT cells grown in 96 well plate were pre-incubated for 15 min with either vehicle (media with DMSO, i.e. total), PK 11195 (PK, 10 mM) or 6T (DAA,
10 mM), and then incubated with either (A) NIR-conPK (100 nM) or (B) NIR-6T (100 nM) for one hour. Cells were then rinsed and RFU at 800 nm read
with an LI-COR OdysseyH Infrared Imaging system. Values are mean6SEM of nine measurements (i.e. three independent experiments, each
performed in triplicate). *p,0.01, significantly different from total, as determined by ANOVA followed by Dunnett’s. (E, F) Kd of NIR-conPK when
using either (E) PK 11195 (10 mM) or (F) DAA1106 (10 mM) to determine non-specific binding. DBT cells grown in a 96 well plate were pre-incubated
for 15 min with either media alone (i.e. total), or addition of PK 11195 or DAA1106, and then incubated with increasing concentration of NIR-conPK
for one hour. Cells were then rinsed and RFU at 800 nm read with an LI-COR OdysseyH Infrared Imaging system. Values are mean6SEM of nine
measurements (i.e. three independent experiments performed in triplicate). Solid line represents specific binding; dotted line with square shows total
binding and dotted line with triangle shows non-specific binding.
doi:10.1371/journal.pone.0008271.g002
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and Fig. S3B,D). In this case, because of the ease of harvesting
large amounts of DBT cells compared to primary microglial cells,
we also performed radioligand binding experiments. Table 2
shows that cytokine treatment did not significantly change the
amount of TSPO (Bmax), nor did it affect the affinity of PK 11195
at TSPO (Ki). This later point is important because such a change
in affinity in response to cytokines has been reported and could
have accounted for the increase in NIR-conPK specific binding
following cytokine treatment [43] (see discussion). Together these
results show that the cytokine-induced increases in NIR-conPK
specific binding do not correlate with changes in either TSPO
expression or the affinity of PK 11195 at TSPO, reinforcing the
conclusion that this novel MI agent binds to a protein distinct from
TSPO.
In the final part of our study, we sought to better understand the
neuroimmune function played by the activated microglia express-
ing more protein targeted by NIR-conPK. To do so, we sought to
correlate increases in NIR-conPK specific binding with increases
in immune effectors released by microglia. Specifically, under
basal conditions, primary microglia in culture released 5 immune
effectors (out of the 24 that we measured), namely IL-1a, IL-6,
monocyte chemoattractant protein 1 (MCP-1), keratinocyte
chemoattractant (KC) and RANTES (also referred to as
chemokine (C-C motif) ligand 5, CCL5) (Fig. 4 and Table S1).
When treating primary microglia with IFNc, TNFa, IFNc+TNFa
or TGFb2 for 24 hrs, we found that these stimuli lead to
differential increases in the release of IL-1a, IL-6, and RANTES,
and did not affect the release of KC and MCP-1 (Fig. 4 and Table
S1). Remarkably, only the cytokine-induced release of IL-1a
correlated with the cytokine-induced increase in NIR-conPK
specific binding (Figs. 3A and 4A). These results suggest that only a
particular subtype of microglia activation profile (here typified by
IL-1a release and induced by IFNc) is associated with an increase
in the protein targeted by NIR-conPK.
Discussion
Cancerous transformation and immune cell activation are
associated with changes in the expression of hundreds to thousands
of proteins [44,45]. Some of these proteins, such as TSPO,
constitute valuable targets for non-invasive in vivo MI and
prognosis. However, when developing new MI agents, it is
essential to systematically verify several criteria: that the selectivity
and affinity of the MI agent at the targeted protein remains
optimal, and that this MI agent reliably monitors any change in
the expression of the targeted protein. Indeed, as we show in this
study, the addition of an imaging moiety, such as a large
Figure 3. No correlation between changes in the specific binding of NIR-conPK and TSPO expression. (A, C) Primary mouse microglia
and DBT (B, D) cells grown in 96 well plate were incubated for 18–24 hrs with either cell culture media (basal), TNFa (5 ng/ml), IFNc (100 Ui/ml), TNFa
plus IFNc, or TGFb2( 1mg/ml). Cells then were pre-incubated for 15 min with either cell culture media (total binding) or DAA1106 (10 mM, non-
specific binding), and then incubated with NIR-conPK for one hour. Cells were rinsed and RFU at 800 nm read with an LI-COR OdysseyH Infrared
Imaging system. Specific binding was calculated by subtracting values of non-specific binding to total binding. Data are mean6SEM of 15
measurements (i.e. five independent experiments performed in triplicate). (C, D) Average optical density and representative western blot (below the
graph) of TSPO expression in cytokine-treated primary microglia (C) or DBT (D) cells. Band corresponding to TSPO migrated at 18 kDa, as previously
described [61].
doi:10.1371/journal.pone.0008271.g003
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toward the targeted protein, while increasing its affinity at a
related protein. Thus, it is important to systematically verify that
the amount of specific binding measured for a new MI agent
indeed fluctuates concomitantly to changes in the expression of the
targeted protein. Another challenge is to increase our understand-
ing of the physiopathological significance of any changes in the
expression of the targeted protein. Our aim was to address these
questions for two MI agents, NIR-conPK and NIR-6T, originally
developed to monitor TSPO expression in intact cells.
Radioligand binding (also known as membrane filtration
receptor assay) constitutes the gold standard for determining the
pharmacological characteristics of newly developed ligands
[33,37]. An obvious advantage of this approach is that it allows
for the thorough manipulation and optimization of variables
known to influence the amount of specific binding of ligands to
their target, including: 1) adjusting the concentration of inorganic
ions, 2) using chemically distinct labeled/unlabeled ligand for
competition studies, 3) avoiding transport and agonist-induced
receptor internalization mechanisms, and 4) excluding allosteric
interactions with some endogenous binding partners [46]. We
performed [
3H]-PK 11195 binding studies with DBT cell
homogenates and found pharmacological characteristics well
within the range of what has been reported for this radioligand
at TSPO (nanomolar Kd for [
3H]-PK 11195, and nanomolar Ki
for PK 11195 and DAA1106) [32]. Using this system, we show
that NIR-6T competes for [
3H]-PK 11195 binding at TSPO in
cell homogenates; whereas NIR-conPK does not.
Conversely, MI binding performed on intact cells serves a
different purpose, because it allows for the pharmacological
characterization of a MI agent at its target under near-
physiological conditions, whereby the ion concentrations and
other parameters are set by the intact cells. Intact cell assays are
advantageous with respect to studying receptors in an environment
more closely related to the native one: the cell membrane has not
been disturbed; intracellular components are in their intrinsic
cytosolic context; and association with effector systems has not
been perturbed. Disadvantages of this system include the
complications linked to the transport of ligands into the cell, and
the multiple regulatory mechanisms that receptors undergo during
the course of a ligand reaching equilibrium (such as: internaliza-
tion, down- or up-regulation, or changes in subcellular distribu-
tion). While G-protein coupled receptors have been somewhat
characterized in respect to membrane versus intact cell binding,
there is a scarcity of data reported on intracellular receptor
binding in intact cells [47,48,49]. TSPO is a 5 transmembrane
component of a pore complex located on the outer membrane of
the mitochondria, associated with several other proteins [50].
While we found that NIR-6T binds with nanomolar affinity to
TSPO in cell homogenates, it did not bind specifically to intact
cells. We propose that this could be due to the relative bulkiness
and hydrophilicity of the 800CW dye preventing the proper
interaction of this MI agent to TSPO when assessed in its intact
cell environment, for TSPO may be bound to regulatory proteins.
One of the most unexpected and interesting findings of our
study is that NIR-conPK did not bind to TSPO in cell
homogenates, but exhibited specific binding when applied to
intact cells. Two sets of data suggest that the specific binding of
NIR-conPK to intact cells is due to its interaction with a protein
distinct, yet related to TSPO. First, the total binding of NIR-
conPK in intact cells is competed-off by PK 11195 and DAA1106.
Second, cytokine-induced changes in NIR-conPK specific binding
does not correlate with cytokine-induced changes in TSPO
expression. Further supporting our conclusion are studies
reporting the existence of proteins pharmacologically-related to
TSPO [51,52,53], one of which might represent the protein
targeted by NIR-conPK that is described here. Thus, we propose
that the addition of the 800CW dye to PK 11195 created a new
interacting site, allowing for its nanomolar binding to a protein
pharmacologically-related to TSPO.
The lack of systematic correlation between the cytokine-induced
increase in NIR-conPK specific binding and TSPO expression
could have been due to a cytokine-induced increase in the binding
affinity of TSPO for PK 11195 and NIR-conPK. Indeed, such an
example has been reported in human neutrophils, whereby N-
formylmethionine-leucine-phenylalanine (f-MLP)-induces an in-
crease in the affinity of TSPO for PK 11195 [43] (most likely
through the induction of a TSPO binding partner [54,55]).
Furthermore, it should be emphasized that we used 100 nM of
NIR-conPK in our MI binding experiments on intact cells and the
Kd of NIR-conPK is 85 nM. Thus, a cytokine-induced increase in
the affinity of TSPO for NIR-conPK would have been reflected by
an increase in the amount of specific binding (100 nM lies within
the linear portion of the dose-response). However, this possibility is
unlikely because we found no change in the affinity of [
3H]-PK
11195 at TSPO in cytokine-treated DBT cells (Table 2). Thus, the
most parsimonious explanation remains that NIR-conPK targets a
protein distinct from, yet related to TSPO.
While the protein targeted by NIR-conPK remains to be
identified, our results show that this MI agent represents a valuable
prototype because it can be used to monitor a particular subtype of
microglial cell activation. The progression of most neuropathol-
ogies involves continuous changes in microglial cell phenotype,
with each phenotype implementing a specific function executed by
these macrophages during the development of complex neuroin-
flammatory responses [56]. For example, microglial cells adopt a
pro-inflammatory profile when encountering IFNc and TNFa,
and are typically involved in the clearance of damaged cells;
whereas microglia adopt an anti-inflammatory and repair
Figure 4. Cytokine and chemokine release by activated
microglia. Primary mouse microglia were incubated for 18–24 hrs
with either vehicle (basal), TNFa (5 ng/ml), IFNc (100 Ui/ml), TNFa plus
IFNc, or TGFb2 (1 ng/ml). Supernatant aliquots were recovered and
amounts of (A) IL-1a,( B) IL-6 and (C) RANTES determined by Luminex
beads. Values are mean6SEM of six measurements (i.e. three
independent experiments, each performed in duplicate). **p,0.01;
*p,0.05, significantly different from basal, as determined by ANOVA
followed by Dunnett’s.
doi:10.1371/journal.pone.0008271.g004
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pro-inflammatory cytokines IFNc leads to an increase in both
NIR-conPK specific binding and IL-1a release, a cytokine known
to be involved in the early phases of many neuroinflammatory
responses [58,59,60]. Thus, fluctuations in NIR-conPK signal
could be used to monitor the early phases of neuroinflammatory
responses. However, before achieving this goal, the affinity of
NIR-conPK at its target will have to be improved as to enhance its
in vivo imaging properties. The development of an improved NIR-
conPK that allows for the monitoring of early neuroinflammatory
responses would represent a valuable asset for the diagnostic of
many neuropathologies.
In conclusion, our results show that NIR-6T does not represent
a viable MI agent to monitor TSPO expression in intact cells, and
that NIR-conPK most likely binds to a protein distinct from, yet
related to TSPO. Our results also suggest that NIR-conPK
represents a valuable prototype for the development of future MI
agents aimed at monitoring changes in a particular subtype of
microglial cell activation process. As such, increasing the number
of MI agents monitoring the various phases that microglial cell
activation typically undergo during neuroinflammatory responses
will be useful for monitoring the progression of various
neuropathologies, and assessing the efficacy of their treatments.
Supporting Information
Figure S1 Chemical structure of PK 11195 and DAA1106
analogues. (A) conPK is a conjugable analogue of PK 11195. In
conPK, the N-methyl, N-isobutyl amide is replaced with with
hexane diamine for conjugation to imaging agents. Arrows
indicate methyl groups on PK 11195 that are not present on
conPK. (B) 6-TSPOmbb732 (6-T) is a conjugable analog of
DAA1106. One methoxy group in DAA1106 is replaced with
hexane diamine for easy conjugation to signaling moieties.
Found at: doi:10.1371/journal.pone.0008271.s001 (0.80 MB TIF)
Figure S2 Linearity of dye fluorescence. Increasing concentra-
tion of NIR-conPK (A) and NIR-6T (B) in black sided optical 96
well plates (in triplicate) was read on the Odyssey Imaging
platform. Relative fluorescence values revealed a linear relation-
ship between dye concentration and emitted fluorescence.
Found at: doi:10.1371/journal.pone.0008271.s002 (0.78 MB TIF)
Figure S3 TSPO expression by qPCR and cell density. (A)
Primary mouse microglia and (B) DBT cells were incubated for
18–24 hrs with either vehicle (basal), TNFa (5 ng/ml), IFNc
(100 Ui/ml), TNFa plus IFNc, or TGFb2 (1 ng/ml), and TSPO
mRNA levels quantified by qPCR, as described in Table 1 legend.
Cell density of cytokine-treated (C) primary mouse microglia and
(D) DBT cells was determined using WST-1, as described in the
Materials and Methods section.
Found at: doi:10.1371/journal.pone.0008271.s003 (0.84 MB TIF)
Table S1 Chemokine release by activated microglia. Primary
mouse microglia were incubated for 18–24 hrs with either vehicle
(basal), TNFa (5 ng/ml), IFNc (100 Ui/ml), TNFa plus IFNc,o r
TGFb2( 1 mg/ml). Supernatant aliquots were recovered and
amount of KC and MCP-1 (pg/ml) determined by Luminex
beads. Values are mean6SEM of six measurements (i.e. three
independent experiments, each performed in duplicate). We found
no significant differences in the release of these chemokines
between basal and respective cytokine-treated conditions, as
determined by ANOVA followed by Dunnett’s.
Found at: doi:10.1371/journal.pone.0008271.s004 (0.86 MB TIF)
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